NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Jami Rubin will join the firm ...

Guggenheim Securities updated their outlook on Immunovant (NASDAQ:IMVT) shares, raising the price target from $44.00 to $46.00 while maintaining a Buy rating on the stock. Currently trading at $23.23, ...

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Jeremy Michael has joined the ...

Guggenheim analyst Robert Drbul maintained a Buy rating on Tapestry (TPR – Research Report) yesterday and set a price target of $90.00. The ...

Guggenheim analyst Shahriar Pourreza maintained a Hold rating on Spire (SR – Research Report) today and set a price target of $67.00. The ...

(MENAFN- GlobeNewsWire - Nasdaq) Guggenheim Securities announced today that Jami Rubin will join the firm's healthcare investment banking practice as a Senior Managing Director NEW YORK ...

(MENAFN- GlobeNewsWire - Nasdaq) Guggenheim Securities announced today that Jeremy Michael has joined the firm's Energy, Power & energy Transition investment banking business as a Senior Managing ...

Guggenheim Securities announced today that Jeremy Michael has joined the firm's Energy, Power & Energy Transition investment banking business as a Senior Managing Director NEW YORK, Jan. 28, 2025 ...